Jane Rhodes, Senior Director of New Initiatives, Value Based Medicine, Biogen
MRC INTEGRATIVE EPIDEMIOLOGY UNIT (IEU)
Thursday, 28th September, 2017 : Seminar Room OS6
Second Floor, Oakfield House
Senior Director of New Initiatives, Value Based Medicine, Biogen
Digital Biomarker Development for Drug Development and Real World Evidence Generation
Value-Based Medicine, Biogen
Digital technologies promise to provide clinical researchers and medical practitioners efficient means for collecting high frequency data that may provide a deeper understanding of disease processes and patients’ functional status collected passively in the patient’s own environment. This is possible because digital technology potentially allows us to capture objective measures that are more sensitive and frequent measures of established clinically meaningful variables or completely novel endpoints that were not previously possible to quantify.
In order to gain wide spread adoption in clinical practice and/or support regulatory approval and label claims using data derived from digital biomarkers, these tools must be validated for their context of use. We have employed biometric monitoring devices for measurement of established and novel digital biomarkers to monitor patients with neurological disease. Here I will describe the opportunities and challenges we have encountered in validating and deploying digital assessments of performance outcome measures for mobility and cognition, and the potential they offer for research, drug development and population health management.
Jane [Relton] Rhodes, PhD, MBA, is Senior Director of New Initiatives in the Value Based Medicine group at Biogen. Dr Rhodes leads a number of initiatives that employ digital solutions to help transform the care of patients with neurological diseases by improving outcomes and demonstrating value to patients and providers.
Dr Rhodes earned her BSc (Pharmacology & Physiology) and PhD (Neurophysiology) from Manchester University, and MBA from Babson College. She began her scientific career in the field of neurology drug discovery research, and worked on novel therapies for stroke, MS, ALS, Parkinson’s disease and Alzheimer’s disease.